Vaccines to prevent infection with the human papillomavirus (HPV) have recently been
approved for use in preventing cervical precancer and cancer. This paper reviews the HPV …

Background: A quadrivalent human papillomavirus (HPV 6/11/16/18) vaccine has recently
received regulatoryapproval in Taiwan for the prevention of cervical carcinoma, high-grade …

Cervical cancer is the second leading cause of cancer death in women in less developed
regions of the world and the leading cause of cancer deaths in GAVI-eligible countries …

Background Given the accumulating evidence that one-dose vaccination could provide high
and sustained protection against human papillomavirus (HPV) infection and related …

Cytology-based screening has reduced cervical cancer mortality in countries able to
implement, sustain and financially support organized programs that achieve broad …

To predict the public health impact on cervical disease by introducing human papillomavirus
(HPV) vaccination in the United Kingdom, we developed a mathematical model that can be …

Despite increasing global attention to the national human papillomavirus (HPV)
immunization program, this program is controversial in Iran. Evidence indicates that HPV …

Objective We assessed the epidemiological and economic impact of a quadrivalent human
papillomavirus (HPV)(6/11/16/18) vaccine for females in preventing cervical cancer, cervical …

Objectives: The objective of this study was to simulate human papillomavirus (HPV) infection
in a heterosexual population and subsequently analyze the incremental costs and effects of …

Cost-effectiveness analysis (CEA) is a well-known, but resource intensive, method for
comparing the costs and health outcomes of health interventions. To build on available …